Shots:

• The P-II/III KidCOVE study evaluated the safety- tolerability- reactogenicity & effectivity of mRNA-1273 in 4753 children aged 6-12yrs. with COVID-19- administered as 28 days apart
• The study met its primary immunogenicity EPs & interim analysis showed a robust neutralizing Ab response after two 50 μg doses of mRNA-1273. The therapy was well tolerated with a safety & tolerability profile that was consistent with the P-III COVE study in adolescents & adults
• Additionally- all participants will be monitored for 12mos. after the 2nd dose to evaluate the long-term protection & safety. The company plans to submit the data to the US FDA- EMA- and other global regulatory imminently

 ­ | Ref: Moderna | Image: Moderna